United Therapeutics (NASDAQ:UTHR) Stock Price Expected to Rise, HC Wainwright Analyst Says

United Therapeutics (NASDAQ:UTHR) had its price objective raised by analysts at HC Wainwright from $525.00 to $600.00 in a report issued on Thursday, MarketBeat Ratings reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price objective suggests a potential upside of 19.20% from the stock’s current price.

Other research analysts have also recently issued reports about the company. Jefferies Financial Group restated a “buy” rating and issued a $575.00 price objective on shares of United Therapeutics in a research note on Wednesday, November 19th. Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a research note on Monday, December 29th. Royal Bank Of Canada raised their price objective on shares of United Therapeutics from $587.00 to $643.00 and gave the stock an “outperform” rating in a research note on Thursday. Wells Fargo & Company increased their target price on United Therapeutics from $423.00 to $466.00 and gave the company an “equal weight” rating in a research report on Thursday. Finally, Oppenheimer upped their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday. Nine analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $533.55.

United Therapeutics Stock Down 5.9%

Shares of United Therapeutics stock traded down $31.76 during trading on Thursday, reaching $503.35. The company’s stock had a trading volume of 342,416 shares, compared to its average volume of 346,632. The company has a 50-day simple moving average of $484.71 and a two-hundred day simple moving average of $444.09. United Therapeutics has a 1-year low of $266.98 and a 1-year high of $537.19. The company has a market cap of $21.67 billion, a price-to-earnings ratio of 19.07, a P/E/G ratio of 2.52 and a beta of 0.85.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, topping the consensus estimate of $6.78 by $0.92. The company had revenue of $790.20 million for the quarter, compared to the consensus estimate of $814.80 million. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. United Therapeutics’s revenue was up 7.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $6.19 EPS. As a group, analysts anticipate that United Therapeutics will post 24.48 earnings per share for the current year.

Insider Activity

In other news, CFO James Edgemond sold 21,000 shares of the business’s stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $479.99, for a total value of $10,079,790.00. Following the sale, the chief financial officer directly owned 8,142 shares of the company’s stock, valued at approximately $3,908,078.58. The trade was a 72.06% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Michael Benkowitz sold 22,500 shares of United Therapeutics stock in a transaction on Monday, December 8th. The shares were sold at an average price of $478.58, for a total value of $10,768,050.00. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 411,954 shares of company stock valued at $199,552,088. 10.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Torren Management LLC acquired a new position in United Therapeutics in the fourth quarter valued at $26,000. Activest Wealth Management boosted its position in shares of United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 56 shares during the period. WealthCollab LLC boosted its position in shares of United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 38 shares during the period. Rakuten Securities Inc. grew its stake in United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 46 shares during the last quarter. Finally, Entrust Financial LLC acquired a new position in United Therapeutics during the fourth quarter worth approximately $31,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics News Roundup

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Q4 EPS beat and record full‑year revenue support the bull case — UTHR reported $7.70 EPS vs. $6.78 expected and full‑year 2025 revenues of $3.18B (11% YoY), which underpinned recent buying interest. BusinessWire press release
• Positive Sentiment: Management set an ambitious target — UTHR is targeting a ~$4B revenue run‑rate by 2027 as several late‑stage and new product launches approach, giving investors a clear growth thesis. Seeking Alpha article
• Positive Sentiment: Analysts raised price targets — RBC and Oppenheimer issued material upside revisions (RBC to $643, Oppenheimer to $600), signaling renewed upside expectations from some institutional research desks. Benzinga coverage
• Positive Sentiment: Unusually heavy call buying around the print indicates bullish options positioning, which can amplify short‑term upside momentum. Zacks options/earnings report
• Neutral Sentiment: Street views remain mixed — several firms maintained Hold/Neutral ratings (BTIG, Morgan Stanley) and some models still show near‑term franchise headwinds despite pipeline upside. TipRanks note
• Neutral Sentiment: Wells Fargo raised its target but kept an Equal‑Weight rating (new $466 target), suggesting limited conviction that the stock will outperform from here. Benzinga coverage
• Negative Sentiment: Revenue missed the quarterly consensus ($790.2M actual vs. ~$814.8M expected), which triggered earlier downside and highlights top‑line execution risk. Investing.com coverage
• Negative Sentiment: Significant insider selling — the COO disclosed multi‑lot sales (including ~14,440 shares) and a director sold shares recently; heavy insider disposals can undermine confidence among some investors. InsiderTrades report

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.